Thông tin thuốc gốc
Chỉ định và Liều dùng
Multiple myeloma
Adult: In combination with dexamethasone, in patient previously treated with at least 2 other treatment regimens including lenalidomide and bortezomib and with disease progression within 60 days of the last completed therapy: Initially, 4 mg once daily for 21 days of a 28-day cycle, continue until disease progression and modify dose according to toxicity. Initiate therapy if absolute neutrophil count (ANC) ≥500 cells/mm3, platelet count ≥50,000 cells/mm3. Interrupt dosing if ANC <500 cells/mm3 (or ANC <1,000 cells/mm3 with fever ≥38.5°C), platelet count <25,000 cells/mm3, then resume at 3 mg once daily after values recover. For each subsequent fall (ANC <500 cells/mm3 and platelet count <25,000 cells/mm3), and other grade 3 or 4 toxicities, interrupt dosing until values recover and resume at 1 mg less than the previous dose. If toxicities still occur at 1 mg once daily dosing, discontinue treatment.
Nhóm bệnh nhân đặc biệt
Patients taking potent CYP1A2 inhibitors: Reduce dose by 50%.
Suy thận
Severe (including patients on haemodialysis): 3 mg once daily, given after haemodialysis.
Suy gan
Mild or moderate (Child-Pugh class A or B): 3 mg once daily. Severe (Child-Pugh class C): 2 mg once daily.
Chống chỉ định
Thận trọng
Patient with risk factors for thromboembolism, history of serious hypersensitivity reactions, cardiac disease or cardiac risk factors, high tumour burden, history of hepatitis B infection. Smokers. Hepatic and severe renal impairment. Lactation.
Tác dụng không mong muốn
Significant: Interstitial lung disease (e.g. pneumonia), bone marrow suppression (e.g. anaemia, neutropenia, thrombocytopenia, leucopenia), pyrexia, dizziness, confusion, hypersensitivity reactions (e.g. angioedema, severe dermatologic reactions), peripheral sensory neuropathy, secondary malignancies (e.g. acute myelogenous leukaemia), thromboembolic events (e.g. DVT, pulmonary embolism), tumour lysis syndrome (TLS), pulmonary oedema, congestive cardiac failure, reactivation of hepatitis B.
Gastrointestinal disorders: Diarrhoea, nausea, constipation, vomiting, oropharyngeal pain.
General disorders and administration site conditions: Fatigue, weakness, fever, hyperhidrosis, chills.
Infections and infestations: Sepsis, herpes zoster.
Investigations: Increased serum bilirubin, creatinine, weight loss.
Metabolism and nutrition disorders: Peripheral oedema, dehydration, decreased appetite, hypercalcaemia, hypo/hyperkalaemia, hyperglycaemia, hyponatraemia, hyperuricaemia.
Musculoskeletal and connective tissue disorders: Back pain, musculoskeletal chest pain, muscle spasms, arthralgia, myasthenia, musculoskeletal and limb pain, ostealgia.
Nervous system disorders: Dizziness, tremor, headache.
Psychiatric disorders: Insomnia, anxiety, confusion.
Renal and urinary disorders: Renal impairment, UTI.
Reproductive system and breast disorders: Pelvic pain.
Respiratory, thoracic and mediastinal disorders: Dyspnoea, cough, epistaxis, bronchitis, nasopharyngitis, upper respiratory tract infection, bronchopneumonia.
Skin and subcutaneous tissue disorders: Rash, dry skin, pruritus.
Potentially Fatal: Hepatic failure.
Thông tin tư vấn bệnh nhân
Avoid blood donation during therapy and for at least 1 month following drug discontinuation. This drug may cause dizziness and confusion, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Perform pregnancy test prior to initiation, weekly during the 1st month then monthly thereafter, and at least 1 month after discontinuation of therapy. Monitor CBC weekly for the 1st 8 weeks of therapy and monthly thereafter; renal function, thyroid function at baseline and every 2-3 months during treatment, LFT monthly. Monitor for signs and symptoms of TLS, neuropathy, thromboembolism.
Tương tác
Increased serum concentration with strong CYP1A2 (e.g. fluvoxamine) and CYP3A4 inhibitors (e.g. ciprofloxacin, ketoconazole).
Tương tác với thức ăn
Delayed absorption with high-fat and high-caloric meals.
Tác dụng
Description: Pomalidomide is a thalidomide analogue with immunomodulatory and direct anti-myeloma tumouricidal activity. The exact mechanism of action has not been fully understood but it is thought to inhibit production of proinflammatory cytokines tumour necrosis factor-α (TNF-α), and angiogenesis; enhance T cell- and natural killer (NK) cell-mediated immunity; inhibit proliferation and induce apoptosis of tumour cells.
Absorption: Rapidly absorbed from the gastrointestinal tract. Food, particularly high-fat and high-caloric meal, decreases rate and extent of absorption. Time to peak plasma concentration: 2-3 hours.
Distribution: Distributed into the semen (approx 67%). Apparent volume of distribution: 62-138 L. Plasma protein binding: 12-44%.
Metabolism: Metabolised in the liver via hydroxylation and subsequent glucuronidation or hydrolysis mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6.
Excretion: Mainly via urine (73%, 2% as unchanged drug); faeces (15%, 8% as unchanged drug). Elimination half-life: Approx 7.5 hours (patient with multiple myeloma); approx 9.5 hours (healthy patient).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Pomalidomide, CID=134780, https://pubchem.ncbi.nlm.nih.gov/compound/Pomalidomide (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C.
This is a cytotoxic drug, avoid contact w/ skin or mucous membranes by wearing gloves and protective equipment. Wash hands before and after handling. Pregnant staff should not handle this product. Any unused portions should be disposed of in accordance with local requirements.
Phân loại MIMS
Liệu pháp miễn dịch trong điều trị ung thư
Phân loại ATC
L04AX06 - pomalidomide ; Belongs to the class of other immunosuppressants.
Tài liệu tham khảo
Anon. Pomalidomide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 31/01/2018.

Buckingham R (ed). Pomalidomide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/01/2018.

Joint Formulary Committee. Pomalidomide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/01/2018.

Pomalyst Capsule (Celgene Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 31/01/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Pomalidomide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in